



Financial Tear Sheet

Corporate Profile

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.

Primary IR Contact


Elissa S. Cote
Vice President, Marketing and External Relations
Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Stock Performance

HSGX (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$2.60
Change (%)	▲ 0.01 (0.39%)
Volume	584
52 Week Low	\$1.55
Market Cap	\$63,884,675
Rolling EPS	0.19
PE Ratio	13.6842
Shares Outstanding	24,571,029

Data as of 02/23/18 9:30 a.m. ET



Recent Headlines & Events

02/20/18 - 8:32 a.m.

[Histogenics Corporation to Present at Upcoming Investor Conferences](#)

01/25/18 - 4:07 p.m.

[Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares](#)

01/22/18 - 7:00 p.m.

[Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock](#)

DATE	TITLE
03/06/18 9:00 a.m. ET	Histogenics Corp at the Canaccord Genuity 2018 Musculoskeletal Conference
03/14/18 8:40 a.m. ET	Histogenics Corp at the Cowen and Company 38th Annual Health Care Conference

SEC Filings

FILING DATE	FORM
02/21/18	4
02/21/18	4
02/21/18	4
02/21/18	4

Corporate Governance

Garheng Kong, M.D., Ph.D.	Chairman – Founder and Managing Partner of HealthQuest Capital
Josh Baltzell	Managing Director, Split Rock Partners
David Gill	Chairman, Audit Committee
Adam Gridley	President and Chief Executive Officer
John Johnson	Independent Member
Michael Lewis	Chairman of Oceana Investment Partners LLP
Kevin Rakin	Independent Member

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)